Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norio Ureshino

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Anticancer Research|July 7, 2021
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel <i>Versus</i> FOLFIRINOX for Recurrent Pancreatic Cancer After ResectionHiroki Taguchi, Taiga Otsuka, Mototsugu Shimokawa, et al.
Anticancer Research|March 28, 2023
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxelYasushi Ide, Taiga Otsuka, Mototsugu Shimokawa, et al.
International Journal of Clinical Oncology|January 23, 2021
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON studyTaiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Pancreas|August 4, 2021
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study)Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, et al.
Scientific Reports|November 8, 2023
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancerMasaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, et al.
Scientific Reports|May 31, 2023
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxelTsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, et al.
Oncology|October 4, 2022
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON StudyJunichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, et al.
Journal of Geriatric Oncology|July 3, 2021
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)Futa Koga, Yasunori Kawaguchi, Mototsugu Shimokawa, et al.
Scientific Reports|July 23, 2024
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxelTaro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, et al.
Oncology|October 20, 2024
Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 StudiesTomonori Araki, Machiko Kawahira, Mototsugu Shimokawa, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Anticancer Research|July 7, 2021
Gemcitabine Plus Nanoparticle Albumin-bound Paclitaxel <i>Versus</i> FOLFIRINOX for Recurrent Pancreatic Cancer After ResectionHiroki Taguchi, Taiga Otsuka, Mototsugu Shimokawa, et al.
Anticancer Research|March 28, 2023
Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxelYasushi Ide, Taiga Otsuka, Mototsugu Shimokawa, et al.
International Journal of Clinical Oncology|January 23, 2021
A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON studyTaiga Otsuka, Tsuyoshi Shirakawa, Mototsugu Shimokawa, et al.
Pancreas|August 4, 2021
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study)Shiho Arima, Machiko Kawahira, Mototsugu Shimokawa, et al.
Scientific Reports|November 8, 2023
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancerMasaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, et al.
Scientific Reports|May 31, 2023
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxelTsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, et al.
Oncology|October 4, 2022
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON StudyJunichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, et al.
Journal of Geriatric Oncology|July 3, 2021
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)Futa Koga, Yasunori Kawaguchi, Mototsugu Shimokawa, et al.
Scientific Reports|July 23, 2024
Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxelTaro Shibuki, Taiga Otsuka, Mototsugu Shimokawa, et al.
Oncology|October 20, 2024
Real-World Analysis of the Correlation between Overall Survival and Progression-Free Survival in Advanced Pancreatic Cancer: Results of NAPOLEON-1 and 2 StudiesTomonori Araki, Machiko Kawahira, Mototsugu Shimokawa, et al.
Pageof 2